Jiangsu Hengrui Medicine
600276.SS
#489
Rank
C$59.27 B
Marketcap
$9.29
Share price
-1.55%
Change (1 day)
3.87%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.12

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.13. In 2022 the company made an earnings per share (EPS) of $0.13 a decrease over its 2021 EPS that were of $0.15.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.12-3.88%
2022$0.13-17.1%
2021$0.15-24.44%
2020$0.2020.3%
2019$0.1725.58%
2018$0.1327.55%
2017$0.1121.64%
2016$0.0869713.57%
2015$0.0765739.86%
2014$0.0547521.33%
2013$0.0451217.7%
2012$0.0383425.56%
2011$0.0305326.22%
2010$0.0241910.3%
2009$0.0219357.92%
2008$0.0138911.06%
2007$0.0125085.81%
2006$0.00673087.94%
2005$0.00358133.97%
2004$0.00267329.78%
2003$0.00205919.78%
2002$0.001719